GPRC6A Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5102095-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA5102095 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
GPRC6A
Classification
Polyclonal
Conjugate
Unconjugated
Gene
GPRC6A
Gene Alias
bA86F4.3; G protein-coupled receptor class C group 6 member A; G protein-coupled receptor, class C, group 6, member A; G protein-coupled receptor, family C, group 6, member A; GPCR; Gprc6a; G-protein coupled receptor family C group 6 member A; G-protein coupled receptor GPCR33; hGPCR33; hGPRC6A; predicted with SOSUI analysis; seven transmembrane helix receptor
Host Species
Rabbit
Purification Method
Affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
222545
Content And Storage
-20°C
Form
Liquid
Applications
Immunocytochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4
Gene Accession No.
Q5T6X5
Gene Symbols
GPRC6A
Immunogen
A synthesized peptide derived from human GPRC6A(Accession Q5T6X5), corresponding to amino acid residues P504-T554.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Antibody detects endogenous levels of total GPRC6A
- GPRC6A is an Orphan-U GPCR with an unknown ligand
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This "eturn-off"e activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.